Sponsored by
Good results from a large Phase 1 trial for IL13Rα2-targeting CAR T cell therapy. This trial enrolled heavily pre-treated recurrent high-grade glioma patients. Most were GBM and ~75% were at second recurrence or more. Half of the patients (29/58) achieved stable disease for at least 2 months, and there were a few partial and complete responses. The study cohort who received the maximum dose had the best median OS at 10.2 months.